Celcuity Inc.(CELC)

Biotechnology · Minneapolis, MN

$73.11-0.52 (-0.70%)

Delayed quote: Oct 6, 2026, 11:31 AM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T15:32:20.339Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:32:20.339Z.

Quote observation: 2026-10-06T15:31:20.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -208,479,000
Quote market capitalization: 3,565,059,484
Total debt · period ending 2026-06-30: 754,385,000
Cash · period ending 2026-06-30: 182,049,000

FMP input reference: bae8dd55c1776b4784265b7d6b815fecf0da21712464e51122872d0292d60ac3

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CELC EBITDA Yield Metrics

EBITDA YIELD

N/A

CELC Competitors' EBITDA Yield

CELC

Celcuity Inc.

Current

Market Cap

$3.57B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IDYA

IDEAYA Biosciences, Inc.

vs CELC

Market Cap

$3.56B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IRTC

iRhythm Technologies, Inc.

vs CELC

Market Cap

$3.53B

EBITDA Yield

0.35%

TTM Avg

0.19%

3Y Avg

0.19%

5Y Avg

0.19%

ACAD

Acadia Pharmaceuticals Inc.

vs CELC

Market Cap

$3.45B

EBITDA Yield

3.14%

TTM Avg

4.14%

3Y Avg

4.45%

5Y Avg

4.45%

CDNA

CareDx, Inc

vs CELC

Market Cap

$3.44B

EBITDA Yield

0.51%

TTM Avg

4.11%

3Y Avg

5.67%

5Y Avg

5.67%

PLSE

Pulse Biosciences, Inc.

vs CELC

Market Cap

$3.41B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PBLS

Parabilis Medicines, Inc.

vs CELC

Market Cap

$3.45B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ICUI

ICU Medical, Inc.

vs CELC

Market Cap

$3.98B

EBITDA Yield

7.33%

TTM Avg

6.29%

3Y Avg

7.56%

5Y Avg

6.15%

DNLI

Denali Therapeutics Inc.

vs CELC

Market Cap

$3.14B

EBITDA Yield

N/A

TTM Avg

0.89%

3Y Avg

0.89%

5Y Avg

0.89%

AMLX

Amylyx Pharmaceuticals, Inc.

vs CELC

Market Cap

$3.11B

EBITDA Yield

N/A

TTM Avg

127.06%

3Y Avg

127.06%

5Y Avg

127.06%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Celcuity Inc. (CELC)	$3.57B	N/A	N/A	N/A	N/A
IDEAYA Biosciences, Inc. (IDYA)vs ›	$3.56B	N/A	N/A	N/A	N/A
iRhythm Technologies, Inc. (IRTC)vs ›	$3.53B	0.35%	0.19%	0.19%	0.19%
Acadia Pharmaceuticals Inc. (ACAD)vs ›	$3.45B	3.14%	4.14%	4.45%	4.45%
CareDx, Inc (CDNA)vs ›	$3.44B	0.51%	4.11%	5.67%	5.67%
Pulse Biosciences, Inc. (PLSE)vs ›	$3.41B	N/A	N/A	N/A	N/A
Parabilis Medicines, Inc. (PBLS)vs ›	$3.45B	N/A	N/A	N/A	N/A
ICU Medical, Inc. (ICUI)vs ›	$3.98B	7.33%	6.29%	7.56%	6.15%
Denali Therapeutics Inc. (DNLI)vs ›	$3.14B	N/A	0.89%	0.89%	0.89%
Amylyx Pharmaceuticals, Inc. (AMLX)vs ›	$3.11B	N/A	127.06%	127.06%	127.06%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

CELC EBITDA Yield Metrics

CELC Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics